The Latest Cardiac and Vascular News
Press release Malmö, Sweden, June 22, 2022 Acarix partners with Strategic Health AK to roll-out CADScor®System across the state of Alaska Acarix continues its US expansion by partnering with Strategic Health AK, a healthcare provider covering tribal and rural areas […]
Acarix continues the US expansion with another commercial partnership now covering Louisiana and parts of Mississippi. This partnership with Bio-Rhythms Inc provides access to cardiology clinics, emergency departments and primary care clinics in geographic areas with high medical need for rapid and cost-effective rule-out of coronary artery disease. […]
A peer-reviewed publication in the September 2021 edition of PharmacoEconomics shows an estimated 12.3£ million savings to the English health care system per 100,000 eligible patients when using the Acarix CADScor system to rule out coronary artery disease (CAD). Coronary […]
Press release (MAR) Malmö, Sweden, November 26, 2020 FDA identifies exclusive code for the CADScor® After yesterday’s announcement and further analysis of the FDA approval, Acarix AB today announce that the company’s marketing approval of the CADScor®System in the US […]
Malmö, Sweden May 11, 2020 Last patient included in Acarix’s exploratory heart failure study SEISMO Acarix AB (publ) today announced that the last patient has been included in the exploratory SEISMO study on a potential heart failure application. The exploratory clinical heart failure trial […]
Malmö, 25 September 2019 Acarix carries out a rights issue of approximately SEK 51.8 million to finance an increased market expansion The board of directors of Acarix AB (“Acarix” or the “Company”) has today, pursuant to the authorization granted by […]
Interim Report, January – September 2018 Malmö, November 14, 2018 Customer evaluation of CADScor®System compares favorably against existing methods “During the quarter we proudly reported that Kristianstad Central Hospital in Sweden evaluated the CADScor®System with a positive outcome. Due to […]
